The estimated Net Worth of William M. Haskel is at least $1.95 millió dollars as of 8 August 2023. Mr Haskel owns over 34,526 units of Paratek Pharmaceuticals stock worth over $996,864 and over the last 13 years he sold PRTK stock worth over $948,194.
Mr has made over 24 trades of the Paratek Pharmaceuticals stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 34,526 units of PRTK stock worth $75,957 on 8 August 2023.
The largest trade he's ever made was selling 37,994 units of Paratek Pharmaceuticals stock on 12 December 2022 worth over $74,848. On average, Mr trades about 6,533 units every 80 days since 2011. As of 8 August 2023 he still owns at least 447,024 units of Paratek Pharmaceuticals stock.
You can see the complete history of Mr Haskel stock trades at the bottom of the page.
William M. Haskel is the Sr. VP, Chief Legal Officer, Gen. Counsel, Corp. Sec. & Chief Compliance Officer at Paratek Pharmaceuticals.
Mr Haskel is 59, he's been the Sr. VP, Chief Legal Officer, Gen. Counsel és Corp. Sec. & Chief Compliance Officer of Paratek Pharmaceuticals since . There are 8 older and 7 younger executives at Paratek Pharmaceuticals. The oldest executive at Paratek Pharmaceuticals Inc. is Sergey Guz, 64, who is the Independent Director.
William's mailing address filed with the SEC is C/O PARATEK PHARMACEUTICALS, INC., 75 PARK PLAZA, 4TH FLOOR, BOSTON, MA, 02116.
Over the last 10 years, insiders at Paratek Pharmaceuticals have traded over $9,410,794 worth of Paratek Pharmaceuticals stock and bought 1,743,576 units worth $13,751,429 . The most active insiders traders include James D Dondero, Bioventures Cayman Ltd Hbm és Evan Loh. On average, Paratek Pharmaceuticals executives and independent directors trade stock every 24 days with the average trade being worth of $63,310. The most recent stock trade was executed by Randall B. Brenner on 8 August 2023, trading 27,603 units of PRTK stock currently worth $60,727.
paratek pharmaceuticals (nasdaq: prtk) is a biopharmaceutical company that develops transformative solutions for patients, both in and out of the hospital, with diseases that are not responsive to current treatments. we focus on drugs that target infectious disease and other difficult to treat conditions. our lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethycyclines, with broad spectrum activity against gram-positive, gram-negative and atypical bacteria. omadacycline is being developed as a once daily, oral and intravenous, empiric monotherapy for community acquired bacterial infections, particularly when antibiotic resistance is of concern. the food and drug administration (fda) granted omadacycline a qualified infectious disease product (qidp) designation and completed two special protocol assessments for its phase 3 clinical trial program.
Paratek Pharmaceuticals executives and other stock owners filed with the SEC include: